Blau Farmacêutica (BLAU3) Q2 2025 earnings summary

Executive summary

• Recurring EBITDA rose 34% year-over-year to BRL 122 million, the highest in four years, with margin at 26.3% and net income up 33% to BRL 63 million.

• Net revenue was BRL 465 million, flat year-over-year, as hospital segment growth was offset by declines in retail, aesthetics, and plasma, impacted by capacity constraints and unplanned production stops.

• Gross margin improved for the seventh consecutive quarter, reaching 40.3%, driven by a favorable sales mix and operational optimization.

• Strategic investments focused on capacity expansion, R&D, and international growth, with CAPEX totaling BRL 100 million, up 44% year-over-year.

• The company will not convert its loan to Prothya into equity, expecting to recover EUR 50 million plus interest, strengthening its cash position.

Financial highlights

• Net revenue for the quarter was BRL 465 million, stable year-over-year due to capacity constraints and unscheduled plant shutdowns.

• Recurring EBITDA for Q2 2025 was BRL 122 million (26.3% margin), up from BRL 91 million (19.6%) in Q2 2024.

• Gross margin: 40.3% (+380 bps year-over-year), with gross profit up 10% to BRL 187 million.

• Net income grew 33% to BRL 63 million, with net margin up 340 bps to 13.6%.

• Working capital increased 5% year-over-year to BRL 941 million, mainly due to higher inventories.

Outlook and guidance

• Capacity expansion at current plants is expected to be completed by year-end, supporting growth through 2028; new Pernambuco plant to address long-term demand.

• Management expects improved performance in the second half, with fewer production stops and potential acceleration in imported product sales.

• Medium- and long-term prospects remain strong, with new product launches, margin gains from monoclonal antibody launches, and international expansion.

• The company expects to return to a net cash position in 2025 after the return of EUR 50 million from Prothya.

• CapEx for the second half expected to average the first half, supporting ongoing capacity investments.